Oral Drug Delivery Resources

  1. The Flux Performance Of Nanoformed And Untreated PRX Solid Suspensions 7/26/2023

    Explore the application of in vitro flux assays to nanoparticles, with data on how the in vitro permeability apparatus can characterize the membrane flux performance of an API formulated as a nanosuspension.

  2. Nanosuspension Dosage Forms: Product Development & Scale Up 2/8/2022

    For drug nanosuspensions, parameters like stabilizer concentration, drug loading, milling speed, milling time, bead diameter/density, and temperature are important formulation and process variables.

  3. Solutions For Accelerated Pharmaceutical Development

    Explore an integrated service package designed to simplify and accelerate the development pathway, even for APIs with challenging properties such as low aqueous solubility and poor bioavailability.

  4. How Various Clinical Study Stages Influence Oral Formulation Approach 4/6/2022

    It’s important for pharmaceutical and biopharmaceutical companies to implement a phase-appropriate approach for early formulation development and later-stage commercial development.

  5. Aligning Pediatric Patient Needs With Drug Development Success 8/15/2024

    Executive Director of Pharmaceutical Sciences Srinivasan Shanmugam, Ph.D., discusses pediatric patient compliance, regulations impacting trial access, excipients within formulations, and more.

  6. Improve Solubility And Spray Drying Throughput For Brick Dust Compounds

    This paper presents three approaches to address poor solubility in organic solvents for spray drying as well as case studies outlining their successful application during development.

  7. Utilizing Nanoparticle Technologies For A More Sustainable Value Chain

    The pharma industry is identifying ways to make processes more sustainable. Learn how nanoparticle engineering technology can both empower sustainability goals and lead to better patient outcomes.

  8. Closing The Duration Gap In FDA-Approved Long-Acting Contraceptives 7/17/2024

    A gap exists between three months and three years in FDA-approved long-acting contraceptives (LACs). A microsphere formulation enables sustained release over a six to twelve-month period.

  9. Considerations In Development & Manufacturing Of Complex Injectables For Early Phase Studies 2/7/2022

    A niche CDMO, with specialized technologies in complex injectable development, will have greater flexibility for successful manufacture of complex injectables in early phase development of therapeutic drugs.

  10. Achieving New Heights By Expanding Services, Talent, And Facilities 4/20/2023

    As you aim to reduce costs and ensure on-time delivery, discover the opportunities for drug formulation and commercial supply that can advance your therapy to the clinic and beyond.